RxDoctor Payments Data

Daniel White, MD

Cardiovascular Disease · Longmont, CONPI 1427060383

Payments from drug & device makers

$813in general payments, 2019–2025

Across 22 payments — averaging $36.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Impulse Dynamics (USA) Inc.$192
  • Edwards Lifesciences$165
  • Boston Scientific$162
  • Abbott$139
  • Heartflow, Inc.$55
  • Biotronik Inc.$20
  • plus $79 from 5 others

What the payments were for

  • Food & beverage$80198%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$813 in reported general payments places this provider in the 35th percentile of 276 cardiovascular disease providers in Colorado.

See all cardiovascular disease providers in Colorado

Medicare billing

Part B allowed, 2024
$120,427
Medicare patients
683
Services billed
1,665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban298$407,876
EntrestoSacubitril/Valsartan104$103,726
JardianceEmpagliflozin71$85,702
Repatha SureclickEvolocumab51$52,966
XareltoRivaroxaban36$51,039
Praluent PenAlirocumab12$7,749
Propafenone Hcl ErPropafenone Hcl20$5,154
Rosuvastatin Calcium376$5,055
Ezetimibe205$4,565
Atorvastatin Calcium281$2,843
Metoprolol Succinate155$2,156
Ranolazine ErRanolazine17$1,797
Nebivolol Hcl53$1,636
Amiodarone Hcl43$1,588
Losartan Potassium179$1,526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$407,876298 claims
NovartisEntresto$16$103,726104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 276 cardiovascular disease providers in Colorado.

Other cardiovascular disease in Longmont

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →